Outlook Therapeutics (NASDAQ:OTLK) Issues Earnings Results

Outlook Therapeutics (NASDAQ:OTLK) posted its quarterly earnings data on Friday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04), Zacks reports.

Outlook Therapeutics Price Performance

Shares of NASDAQ:OTLK traded up $0.04 during trading on Friday, reaching $1.88. 547,657 shares of the company were exchanged, compared to its average volume of 871,661. The business’s fifty day simple moving average is $1.86 and its 200-day simple moving average is $4.56. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The firm has a market capitalization of $60.12 million, a PE ratio of -0.21 and a beta of 0.58.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OTLK. BTIG Research lowered their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. Finally, Guggenheim restated a “buy” rating and set a $12.00 target price on shares of Outlook Therapeutics in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $27.40.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.